


Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:Low (<= 3000.000 IU/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:Low (<= 3000.000 IU/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:High (> 3000.000 IU/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:High (> 3000.000 IU/week)








図 2.7.3.6-38　前治療として使用した ESA の種類別の平均用量（試験 19352、FAS）

表 2.7.3.6-79 前治療として使用したESAの種類別のモリデュスタットの平均用量の分布（試験19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=51)	Week 0	51	75.00	0.00	75.0	75.00	75.0
	Week 2	50	74.50	3.54	50.0	75.00	75.0
	Week 4	50	78.00	18.65	0.0	75.00	100.0
	Week 6	49	73.47	24.16	0.0	75.00	100.0
	Week 8	48	82.29	43.75	0.0	75.00	150.0
	Week 10	48	84.38	38.12	0.0	75.00	150.0
	Week 12	46	83.70	54.32	0.0	75.00	200.0
	Week 14	44	87.50	51.29	0.0	75.00	200.0
	Week 16	43	83.72	56.14	0.0	75.00	200.0
	Week 18	43	84.30	53.74	0.0	75.00	200.0
	Week 20	43	79.07	56.61	0.0	75.00	200.0
	Week 22	43	79.94	55.51	0.0	75.00	200.0
	Week 24	43	78.31	55.07	0.0	75.00	200.0
	Week 26	42	76.31	51.54	0.0	75.00	200.0
	Week 28	42	72.38	53.33	0.0	75.00	200.0
	Week 30	42	71.79	50.20	0.0	75.00	200.0
	Week 32	42	68.99	49.00	0.0	75.00	200.0
	Week 33	41	70.06	49.11	0.0	75.00	200.0
	Week 34	41	66.52	41.47	0.0	75.00	150.0
	Week 35	41	66.52	41.47	0.0	75.00	150.0
	Week 36	41	64.45	43.35	0.0	50.00	150.0
	Week 38	41	62.01	41.56	0.0	50.00	150.0
	Week 40	40	65.19	49.91	0.0	50.00	200.0
	Week 42	40	65.31	49.75	0.0	50.00	200.0
	Week 44	39	60.64	49.11	0.0	50.00	200.0
	Week 46	39	60.64	49.11	0.0	50.00	200.0
	Week 48	39	61.15	48.62	0.0	50.00	200.0
	Week 50	39	57.31	47.32	0.0	50.00	200.0

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=35)	Week 0	35	75.00	0.00	75.0	75.00	75.0
	Week 2	33	75.00	0.00	75.0	75.00	75.0
	Week 4	32	82.03	15.86	50.0	75.00	100.0
	Week 6	30	80.00	21.17	0.0	75.00	100.0
	Week 8	27	95.37	41.62	0.0	75.00	150.0
	Week 10	27	96.30	39.65	25.0	75.00	150.0
	Week 12	27	114.81	61.34	25.0	100.00	200.0
	Week 14	26	106.73	55.93	25.0	75.00	200.0
	Week 16	26	106.73	62.67	25.0	100.00	200.0
	Week 18	26	105.77	62.97	25.0	87.50	200.0
	Week 20	26	100.96	71.58	0.0	75.00	200.0
	Week 22	26	100.96	71.58	0.0	75.00	200.0
	Week 24	26	94.23	66.07	0.0	75.00	200.0
	Week 26	26	93.27	66.92	0.0	75.00	200.0
	Week 28	25	92.00	66.82	0.0	75.00	200.0
	Week 30	25	88.00	69.27	0.0	75.00	200.0
	Week 32	25	90.00	67.31	0.0	75.00	200.0
	Week 33	25	90.00	67.31	0.0	75.00	200.0
	Week 34	25	93.00	64.76	25.0	75.00	200.0
	Week 35	25	93.00	64.76	25.0	75.00	200.0
	Week 36	25	96.00	62.78	25.0	75.00	200.0
	Week 38	25	96.00	62.78	25.0	75.00	200.0
	Week 40	23	104.35	63.81	25.0	100.00	200.0
	Week 42	22	106.82	64.17	25.0	100.00	200.0
	Week 44	22	109.09	68.81	25.0	100.00	200.0
	Week 46	22	109.09	68.81	25.0	100.00	200.0
	Week 48	22	107.95	69.17	25.0	87.50	200.0
	Week 50	22	107.95	69.17	25.0	87.50	200.0

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=86)	Week 0	86	75.00	0.00	75.0	75.00	75.0
	Week 2	83	74.70	2.74	50.0	75.00	75.0
	Week 4	82	79.57	17.62	0.0	75.00	100.0
	Week 6	79	75.95	23.15	0.0	75.00	100.0
	Week 8	75	87.00	43.18	0.0	75.00	150.0
	Week 10	75	88.67	38.84	0.0	75.00	150.0
	Week 12	73	95.21	58.58	0.0	75.00	200.0
	Week 14	70	94.64	53.48	0.0	75.00	200.0
	Week 16	69	92.39	59.30	0.0	75.00	200.0
	Week 18	69	92.39	57.89	0.0	75.00	200.0
	Week 20	69	87.32	63.07	0.0	75.00	200.0
	Week 22	69	87.86	62.39	0.0	75.00	200.0
	Week 24	69	84.31	59.49	0.0	75.00	200.0
	Week 26	68	82.79	58.01	0.0	75.00	200.0
	Week 28	67	79.70	59.00	0.0	75.00	200.0
	Week 30	67	77.84	58.08	0.0	75.00	200.0
	Week 32	67	76.83	56.96	0.0	75.00	200.0
	Week 33	66	77.61	57.03	0.0	75.00	200.0
	Week 34	66	76.55	52.67	0.0	75.00	200.0
	Week 35	66	76.55	52.67	0.0	75.00	200.0
	Week 36	66	76.40	53.38	0.0	75.00	200.0
	Week 38	66	74.89	52.86	0.0	75.00	200.0
	Week 40	63	79.48	58.08	0.0	75.00	200.0
	Week 42	62	80.04	58.32	0.0	75.00	200.0
	Week 44	61	78.11	61.12	0.0	75.00	200.0
	Week 46	61	78.11	61.12	0.0	75.00	200.0
	Week 48	61	78.03	60.71	0.0	75.00	200.0
	Week 50	61	75.57	60.78	0.0	75.00	200.0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=10)	Week 0	10	75.00	0.00	75.0	75.00	75.0
	Week 2	10	72.50	7.91	50.0	75.00	75.0
	Week 4	10	72.50	14.19	50.0	75.00	100.0
	Week 6	10	67.50	26.48	0.0	75.00	100.0
	Week 8	10	65.00	39.44	0.0	75.00	150.0
	Week 10	10	67.50	35.45	25.0	75.00	150.0
	Week 12	10	66.25	55.29	0.0	75.00	200.0
	Week 14	10	66.25	55.29	0.0	75.00	200.0
	Week 16	10	61.75	59.68	0.0	62.50	200.0
	Week 18	10	58.00	59.64	0.0	62.50	200.0
	Week 20	10	59.75	59.05	5.0	50.00	200.0
	Week 22	10	59.75	59.05	5.0	50.00	200.0
	Week 24	10	51.75	60.92	0.0	25.00	200.0
	Week 26	10	49.25	62.63	0.0	25.00	200.0
	Week 28	10	45.50	63.69	0.0	18.75	200.0
	Week 30	10	45.50	63.69	0.0	18.75	200.0
	Week 32	10	43.50	64.71	0.0	12.50	200.0
	Week 33	10	43.50	64.71	0.0	12.50	200.0
	Week 34	10	43.50	64.71	0.0	12.50	200.0
	Week 35	10	43.50	64.71	0.0	12.50	200.0
	Week 36	10	42.75	65.15	0.0	8.75	200.0
	Week 38	10	42.75	65.15	0.0	8.75	200.0
	Week 40	10	42.25	65.49	0.0	8.75	200.0
	Week 42	10	42.25	65.49	0.0	8.75	200.0
	Week 44	10	39.75	63.49	0.0	8.75	200.0
	Week 46	10	39.75	63.49	0.0	8.75	200.0
	Week 48	10	16.75	26.09	0.0	2.50	75.0
	Week 50	10	16.75	26.09	0.0	2.50	75.0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=9)	Week 0	9	75.00	0.00	75.0	75.00	75.0
	Week 2	9	75.00	0.00	75.0	75.00	75.0
	Week 4	9	80.56	11.02	75.0	75.00	100.0
	Week 6	9	80.56	11.02	75.0	75.00	100.0
	Week 8	9	80.56	30.05	50.0	75.00	150.0
	Week 10	9	77.78	31.73	50.0	75.00	150.0
	Week 12	9	66.67	30.62	0.0	75.00	100.0
	Week 14	9	55.56	37.03	0.0	50.00	100.0
	Week 16	9	58.33	59.95	0.0	50.00	150.0
	Week 18	9	66.67	53.03	0.0	50.00	150.0
	Week 20	9	80.56	75.81	0.0	50.00	200.0
	Week 22	9	83.33	72.89	25.0	50.00	200.0
	Week 24	9	90.28	82.39	12.5	25.00	200.0
	Week 26	9	88.89	83.72	12.5	25.00	200.0
	Week 28	9	87.50	73.42	12.5	50.00	200.0
	Week 30	9	76.39	65.68	12.5	50.00	200.0
	Week 32	9	81.11	63.92	5.0	75.00	200.0
	Week 33	9	81.11	63.92	5.0	75.00	200.0
	Week 34	9	81.11	63.92	5.0	75.00	200.0
	Week 35	9	81.11	63.92	5.0	75.00	200.0
	Week 36	9	70.00	68.74	0.0	50.00	200.0
	Week 38	9	75.56	64.25	5.0	50.00	200.0
	Week 40	9	78.33	63.54	5.0	75.00	200.0
	Week 42	9	72.78	68.33	0.0	75.00	200.0
	Week 44	9	72.78	68.33	0.0	75.00	200.0
	Week 46	9	75.56	65.45	5.0	75.00	200.0
	Week 48	9	70.00	54.83	5.0	75.00	150.0
	Week 50	9	70.00	54.83	5.0	75.00	150.0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=19)	Week 0	19	75.00	0.00	75.0	75.00	75.0
	Week 2	19	73.68	5.74	50.0	75.00	75.0
	Week 4	19	76.32	13.11	50.0	75.00	100.0
	Week 6	19	73.68	21.20	0.0	75.00	100.0
	Week 8	19	72.37	35.25	0.0	75.00	150.0
	Week 10	19	72.37	33.22	25.0	75.00	150.0
	Week 12	19	66.45	44.11	0.0	75.00	200.0
	Week 14	19	61.18	46.57	0.0	75.00	200.0
	Week 16	19	60.13	58.15	0.0	50.00	200.0
	Week 18	19	62.11	55.21	0.0	50.00	200.0
	Week 20	19	69.61	66.42	0.0	50.00	200.0
	Week 22	19	70.92	65.20	5.0	50.00	200.0
	Week 24	19	70.00	72.55	0.0	25.00	200.0
	Week 26	19	68.03	74.09	0.0	25.00	200.0
	Week 28	19	65.39	69.92	0.0	25.00	200.0
	Week 30	19	60.13	64.78	0.0	25.00	200.0
	Week 32	19	61.32	65.44	0.0	25.00	200.0
	Week 33	19	61.32	65.44	0.0	25.00	200.0
	Week 34	19	61.32	65.44	0.0	25.00	200.0
	Week 35	19	61.32	65.44	0.0	25.00	200.0
	Week 36	19	55.66	66.47	0.0	25.00	200.0
	Week 38	19	58.29	65.12	0.0	25.00	200.0
	Week 40	19	59.34	65.44	0.0	25.00	200.0
	Week 42	19	56.71	66.82	0.0	25.00	200.0
	Week 44	19	55.39	66.17	0.0	25.00	200.0
	Week 46	19	56.71	65.25	0.0	25.00	200.0
	Week 48	19	41.97	49.22	0.0	25.00	150.0
	Week 50	19	41.97	49.22	0.0	25.00	150.0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=25)	Week 0	25	75.00	0.00	75.0	75.00	75.0
	Week 2	24	71.88	8.45	50.0	75.00	75.0
	Week 4	24	66.67	29.18	0.0	75.00	100.0
	Week 6	24	66.67	29.18	0.0	75.00	100.0
	Week 8	22	57.95	38.87	0.0	75.00	150.0
	Week 10	21	55.95	38.65	0.0	75.00	150.0
	Week 12	21	58.33	45.64	0.0	75.00	200.0
	Week 14	21	58.33	45.64	0.0	75.00	200.0
	Week 16	21	59.52	48.40	0.0	75.00	200.0
	Week 18	21	59.52	48.40	0.0	75.00	200.0
	Week 20	21	61.90	49.76	0.0	75.00	200.0
	Week 22	21	61.90	49.76	0.0	75.00	200.0
	Week 24	21	66.07	56.06	0.0	75.00	200.0
	Week 26	20	65.63	57.48	0.0	62.50	200.0
	Week 28	20	63.38	53.12	0.0	50.00	200.0
	Week 30	19	63.42	55.05	0.0	50.00	200.0
	Week 32	19	62.37	56.00	0.0	50.00	200.0
	Week 33	19	61.71	56.54	0.0	50.00	200.0
	Week 34	19	61.71	56.54	0.0	50.00	200.0
	Week 35	19	61.05	57.21	0.0	50.00	200.0
	Week 36	19	63.03	57.76	0.0	50.00	200.0
	Week 38	19	62.63	58.15	0.0	50.00	200.0
	Week 40	19	61.97	54.36	0.0	75.00	200.0
	Week 42	19	61.97	54.36	0.0	75.00	200.0
	Week 44	19	57.76	50.48	0.0	75.00	200.0
	Week 46	19	56.45	51.02	0.0	75.00	200.0
	Week 48	19	56.05	55.31	0.0	50.00	200.0
	Week 50	19	55.00	56.12	0.0	50.00	200.0


Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=23)	Week 0	23	75.00	0.00	75.0	75.00	75.0
	Week 2	23	75.00	0.00	75.0	75.00	75.0
	Week 4	23	88.04	12.77	75.0	100.00	100.0
	Week 6	23	88.04	12.77	75.0	100.00	100.0
	Week 8	21	108.33	35.65	50.0	100.00	150.0
	Week 10	21	108.33	35.65	50.0	100.00	150.0
	Week 12	20	120.00	63.14	0.0	100.00	200.0
	Week 14	20	120.00	63.14	0.0	100.00	200.0
	Week 16	20	122.50	69.25	0.0	150.00	200.0
	Week 18	20	123.75	67.12	25.0	150.00	200.0
	Week 20	20	118.75	66.82	25.0	150.00	200.0
	Week 22	19	103.95	73.25	0.0	100.00	200.0
	Week 24	19	109.21	76.02	0.0	150.00	200.0
	Week 26	19	109.21	75.56	0.0	150.00	200.0
	Week 28	19	110.53	73.27	25.0	100.00	200.0
	Week 30	19	107.89	70.74	25.0	100.00	200.0
	Week 32	19	105.26	74.34	0.0	75.00	200.0
	Week 33	19	105.26	74.34	0.0	75.00	200.0
	Week 34	19	105.92	73.41	12.5	75.00	200.0
	Week 35	19	105.92	73.41	12.5	75.00	200.0
	Week 36	19	101.97	73.39	12.5	75.00	200.0
	Week 38	19	101.97	73.39	12.5	75.00	200.0
	Week 40	18	96.53	71.46	12.5	75.00	200.0
	Week 42	18	92.36	74.89	0.0	75.00	200.0
	Week 44	17	91.91	75.12	0.0	75.00	200.0
	Week 46	17	91.91	75.12	0.0	75.00	200.0
	Week 48	16	91.41	72.56	12.5	50.00	200.0
	Week 50	16	91.41	72.56	12.5	50.00	200.0


Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=48)	Week 0	48	75.00	0.00	75.0	75.00	75.0
	Week 2	47	73.40	6.18	50.0	75.00	75.0
	Week 4	47	77.13	24.91	0.0	75.00	100.0
	Week 6	47	77.13	24.91	0.0	75.00	100.0
	Week 8	43	82.56	44.83	0.0	75.00	150.0
	Week 10	42	82.14	45.29	0.0	75.00	150.0
	Week 12	41	88.41	62.52	0.0	75.00	200.0
	Week 14	41	88.41	62.52	0.0	75.00	200.0
	Week 16	41	90.24	66.82	0.0	75.00	200.0
	Week 18	41	90.85	66.09	0.0	75.00	200.0
	Week 20	41	89.63	64.71	0.0	75.00	200.0
	Week 22	40	81.88	64.79	0.0	75.00	200.0
	Week 24	40	86.56	68.95	0.0	75.00	200.0
	Week 26	39	86.86	69.59	0.0	75.00	200.0
	Week 28	39	86.35	67.26	0.0	75.00	200.0
	Week 30	38	85.66	66.45	0.0	75.00	200.0
	Week 32	38	83.82	68.46	0.0	75.00	200.0
	Week 33	38	83.49	68.78	0.0	75.00	200.0
	Week 34	38	83.82	68.40	0.0	75.00	200.0
	Week 35	38	83.49	68.78	0.0	75.00	200.0
	Week 36	38	82.50	68.06	0.0	75.00	200.0
	Week 38	38	82.30	68.28	0.0	75.00	200.0
	Week 40	37	78.78	64.77	0.0	75.00	200.0
	Week 42	37	76.76	66.06	0.0	75.00	200.0
	Week 44	36	73.89	64.73	0.0	75.00	200.0
	Week 46	36	73.19	65.12	0.0	75.00	200.0
	Week 48	35	72.21	65.28	0.0	50.00	200.0
	Week 50	35	71.64	65.79	0.0	50.00	200.0


Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 15.000 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 15.625 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 15.625 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 15.625 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 15.625 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:Low (<= 3000.000 IU/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:Low (<= 3000.000 IU/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:High (> 3000.000 IU/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin alfa or beta
Categories:High (> 3000.000 IU/week)








図 2.7.3.6-39 前治療として使用した ESA の種類別の各来院での用量の分布（試験 19352、FAS）

表 2.7.3.6-80　前治療として使用したESAの種類別のモリデュスタットの各来院での用量（試験19352、FAS）

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	51	0	0	0	0	0	51 (100.0%)	0	0	0
Week 2	50	0	0	0	0	1 (2.0%)	49 (98.0%)	0	0	0
Week 4	50	1 (2.0%)	0	0	0	5 (10.0%)	30 (60.0%)	14 (28.0%)	0	0
Week 6	49	3 (6.1%)	0	0	0	6 (12.2%)	28 (57.1%)	12 (24.5%)	0	0
Week 8	48	5 (10.4%)	0	0	0	7 (14.6%)	20 (41.7%)	6 (12.5%)	10 (20.8%)	0
Week 10	48	2 (4.2%)	0	0	0	10 (20.8%)	20 (41.7%)	7 (14.6%)	9 (18.8%)	0
Week 12	46	4 (8.7%)	0	0	3 (6.5%)	10 (21.7%)	13 (28.3%)	6 (13.0%)	6 (13.0%)	4 (8.7%)
Week 14	44	1 (2.3%)	0	0	3 (6.8%)	12 (27.3%)	13 (29.5%)	5 (11.4%)	6 (13.6%)	4 (9.1%)
Week 16	43	4 (9.3%)	0	0	4 (9.3%)	8 (18.6%)	14 (32.6%)	1 (2.3%)	9 (20.9%)	3 (7.0%)
Week 18	43	3 (7.0%)	0	0	4 (9.3%)	8 (18.6%)	15 (34.9%)	2 (4.7%)	8 (18.6%)	3 (7.0%)
Week 20	43	4 (9.3%)	0	2 (4.7%)	4 (9.3%)	9 (20.9%)	9 (20.9%)	5 (11.6%)	7 (16.3%)	3 (7.0%)
Week 22	43	2 (4.7%)	0	3 (7.0%)	5 (11.6%)	9 (20.9%)	9 (20.9%)	5 (11.6%)	7 (16.3%)	3 (7.0%)
Week 24	43	2 (4.7%)	1 (2.3%)	3 (7.0%)	4 (9.3%)	9 (20.9%)	9 (20.9%)	6 (14.0%)	6 (14.0%)	3 (7.0%)
Week 26	42	2 (4.8%)	1 (2.4%)	2 (4.8%)	4 (9.5%)	10 (23.8%)	9 (21.4%)	6 (14.3%)	6 (14.3%)	2 (4.8%)
Week 28	42	2 (4.8%)	3 (7.1%)	2 (4.8%)	4 (9.5%)	8 (19.0%)	10 (23.8%)	7 (16.7%)	3 (7.1%)	3 (7.1%)
Week 30	42	1 (2.4%)	3 (7.1%)	2 (4.8%)	5 (11.9%)	8 (19.0%)	10 (23.8%)	7 (16.7%)	4 (9.5%)	2 (4.8%)
Week 32	42	3 (7.1%)	2 (4.8%)	1 (2.4%)	5 (11.9%)	8 (19.0%)	12 (28.6%)	6 (14.3%)	3 (7.1%)	2 (4.8%)
Week 33	41	3 (7.3%)	2 (4.9%)	1 (2.4%)	4 (9.8%)	8 (19.5%)	12 (29.3%)	6 (14.6%)	3 (7.3%)	2 (4.9%)
Week 34	41	2 (4.9%)	3 (7.3%)	1 (2.4%)	4 (9.8%)	8 (19.5%)	12 (29.3%)	7 (17.1%)	4 (9.8%)	0
Week 35	41	2 (4.9%)	3 (7.3%)	1 (2.4%)	4 (9.8%)	8 (19.5%)	12 (29.3%)	7 (17.1%)	4 (9.8%)	0
Week 36	41	4 (9.8%)	1 (2.4%)	3 (7.3%)	2 (4.9%)	12 (29.3%)	6 (14.6%)	9 (22.0%)	4 (9.8%)	0
Week 38	41	4 (9.8%)	1 (2.4%)	3 (7.3%)	3 (7.3%)	11 (26.8%)	7 (17.1%)	9 (22.0%)	3 (7.3%)	0
Week 40	40	3 (7.5%)	4 (10.0%)	1 (2.5%)	5 (12.5%)	8 (20.0%)	6 (15.0%)	8 (20.0%)	4 (10.0%)	1 (2.5%)
Week 42	40	2 (5.0%)	5 (12.5%)	1 (2.5%)	5 (12.5%)	8 (20.0%)	6 (15.0%)	8 (20.0%)	4 (10.0%)	1 (2.5%)
Week 44	39	5 (12.8%)	3 (7.7%)	0	7 (17.9%)	5 (12.8%)	9 (23.1%)	6 (15.4%)	3 (7.7%)	1 (2.6%)
Week 46	39	5 (12.8%)	3 (7.7%)	0	7 (17.9%)	5 (12.8%)	9 (23.1%)	6 (15.4%)	3 (7.7%)	1 (2.6%)
Week 48	39	6 (15.4%)	2 (5.1%)	0	5 (12.8%)	8 (20.5%)	8 (20.5%)	6 (15.4%)	3 (7.7%)	1 (2.6%)
Week 50	39	7 (17.9%)	2 (5.1%)	0	5 (12.8%)	8 (20.5%)	8 (20.5%)	6 (15.4%)	2 (5.1%)	1 (2.6%)

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

Visit	n	0 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	35	0	0	0	35 (100.0%)	0	0	0
Week 2	33	0	0	0	33 (100.0%)	0	0	0
Week 4	32	0	0	3 (9.4%)	17 (53.1%)	12 (37.5%)	0	0
Week 6	30	1 (3.3%)	0	2 (6.7%)	16 (53.3%)	11 (36.7%)	0	0
Week 8	27	1 (3.7%)	1 (3.7%)	1 (3.7%)	12 (44.4%)	4 (14.8%)	8 (29.6%)	0
Week 10	27	0	2 (7.4%)	1 (3.7%)	12 (44.4%)	4 (14.8%)	8 (29.6%)	0
Week 12	27	0	2 (7.4%)	3 (11.1%)	8 (29.6%)	3 (11.1%)	4 (14.8%)	7 (25.9%)
Week 14	26	0	2 (7.7%)	3 (11.5%)	9 (34.6%)	2 (7.7%)	6 (23.1%)	4 (15.4%)
Week 16	26	0	3 (11.5%)	5 (19.2%)	4 (15.4%)	5 (19.2%)	3 (11.5%)	6 (23.1%)
Week 18	26	0	3 (11.5%)	5 (19.2%)	5 (19.2%)	4 (15.4%)	3 (11.5%)	6 (23.1%)
Week 20	26	2 (7.7%)	4 (15.4%)	3 (11.5%)	5 (19.2%)	3 (11.5%)	2 (7.7%)	7 (26.9%)
Week 22	26	2 (7.7%)	4 (15.4%)	3 (11.5%)	5 (19.2%)	3 (11.5%)	2 (7.7%)	7 (26.9%)
Week 24	26	1 (3.8%)	5 (19.2%)	5 (19.2%)	3 (11.5%)	4 (15.4%)	3 (11.5%)	5 (19.2%)
Week 26	26	1 (3.8%)	6 (23.1%)	4 (15.4%)	3 (11.5%)	4 (15.4%)	3 (11.5%)	5 (19.2%)
Week 28	25	1 (4.0%)	6 (24.0%)	3 (12.0%)	4 (16.0%)	4 (16.0%)	2 (8.0%)	5 (20.0%)
Week 30	25	2 (8.0%)	6 (24.0%)	3 (12.0%)	4 (16.0%)	3 (12.0%)	2 (8.0%)	5 (20.0%)
Week 32	25	1 (4.0%)	6 (24.0%)	4 (16.0%)	4 (16.0%)	3 (12.0%)	2 (8.0%)	5 (20.0%)
Week 33	25	1 (4.0%)	6 (24.0%)	4 (16.0%)	4 (16.0%)	3 (12.0%)	2 (8.0%)	5 (20.0%)
Week 34	25	0	6 (24.0%)	4 (16.0%)	5 (20.0%)	3 (12.0%)	2 (8.0%)	5 (20.0%)
Week 35	25	0	6 (24.0%)	4 (16.0%)	5 (20.0%)	3 (12.0%)	2 (8.0%)	5 (20.0%)
Week 36	25	0	4 (16.0%)	6 (24.0%)	4 (16.0%)	4 (16.0%)	2 (8.0%)	5 (20.0%)
Week 38	25	0	4 (16.0%)	6 (24.0%)	4 (16.0%)	4 (16.0%)	2 (8.0%)	5 (20.0%)
Week 40	23	0	3 (13.0%)	6 (26.1%)	1 (4.3%)	5 (21.7%)	3 (13.0%)	5 (21.7%)
Week 42	22	0	3 (13.6%)	5 (22.7%)	1 (4.5%)	5 (22.7%)	3 (13.6%)	5 (22.7%)
Week 44	22	0	4 (18.2%)	4 (18.2%)	2 (9.1%)	3 (13.6%)	3 (13.6%)	6 (27.3%)
Week 46	22	0	4 (18.2%)	4 (18.2%)	2 (9.1%)	3 (13.6%)	3 (13.6%)	6 (27.3%)
Week 48	22	0	4 (18.2%)	4 (18.2%)	3 (13.6%)	2 (9.1%)	3 (13.6%)	6 (27.3%)
Week 50	22	0	4 (18.2%)	4 (18.2%)	3 (13.6%)	2 (9.1%)	3 (13.6%)	6 (27.3%)

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	86	0	0	0	0	0	86 (100.0%)	0	0	0
Week 2	83	0	0	0	0	1 (1.2%)	82 (98.8%)	0	0	0
Week 4	82	1 (1.2%)	0	0	0	8 (9.8%)	47 (57.3%)	26 (31.7%)	0	0
Week 6	79	4 (5.1%)	0	0	0	8 (10.1%)	44 (55.7%)	23 (29.1%)	0	0
Week 8	75	6 (8.0%)	0	0	1 (1.3%)	8 (10.7%)	32 (42.7%)	10 (13.3%)	18 (24.0%)	0
Week 10	75	2 (2.7%)	0	0	2 (2.7%)	11 (14.7%)	32 (42.7%)	11 (14.7%)	17 (22.7%)	0
Week 12	73	4 (5.5%)	0	0	5 (6.8%)	13 (17.8%)	21 (28.8%)	9 (12.3%)	10 (13.7%)	11 (15.1%)
Week 14	70	1 (1.4%)	0	0	5 (7.1%)	15 (21.4%)	22 (31.4%)	7 (10.0%)	12 (17.1%)	8 (11.4%)
Week 16	69	4 (5.8%)	0	0	7 (10.1%)	13 (18.8%)	18 (26.1%)	6 (8.7%)	12 (17.4%)	9 (13.0%)
Week 18	69	3 (4.3%)	0	0	7 (10.1%)	13 (18.8%)	20 (29.0%)	6 (8.7%)	11 (15.9%)	9 (13.0%)
Week 20	69	6 (8.7%)	0	2 (2.9%)	8 (11.6%)	12 (17.4%)	14 (20.3%)	8 (11.6%)	9 (13.0%)	10 (14.5%)
Week 22	69	4 (5.8%)	0	3 (4.3%)	9 (13.0%)	12 (17.4%)	14 (20.3%)	8 (11.6%)	9 (13.0%)	10 (14.5%)
Week 24	69	3 (4.3%)	1 (1.4%)	3 (4.3%)	9 (13.0%)	14 (20.3%)	12 (17.4%)	10 (14.5%)	9 (13.0%)	8 (11.6%)
Week 26	68	3 (4.4%)	1 (1.5%)	2 (2.9%)	10 (14.7%)	14 (20.6%)	12 (17.6%)	10 (14.7%)	9 (13.2%)	7 (10.3%)
Week 28	67	3 (4.5%)	3 (4.5%)	2 (3.0%)	10 (14.9%)	11 (16.4%)	14 (20.9%)	11 (16.4%)	5 (7.5%)	8 (11.9%)
Week 30	67	3 (4.5%)	3 (4.5%)	2 (3.0%)	11 (16.4%)	11 (16.4%)	14 (20.9%)	10 (14.9%)	6 (9.0%)	7 (10.4%)
Week 32	67	4 (6.0%)	2 (3.0%)	1 (1.5%)	11 (16.4%)	12 (17.9%)	16 (23.9%)	9 (13.4%)	5 (7.5%)	7 (10.4%)
Week 33	66	4 (6.1%)	2 (3.0%)	1 (1.5%)	10 (15.2%)	12 (18.2%)	16 (24.2%)	9 (13.6%)	5 (7.6%)	7 (10.6%)
Week 34	66	2 (3.0%)	3 (4.5%)	1 (1.5%)	10 (15.2%)	12 (18.2%)	17 (25.8%)	10 (15.2%)	6 (9.1%)	5 (7.6%)
Week 35	66	2 (3.0%)	3 (4.5%)	1 (1.5%)	10 (15.2%)	12 (18.2%)	17 (25.8%)	10 (15.2%)	6 (9.1%)	5 (7.6%)
Week 36	66	4 (6.1%)	1 (1.5%)	3 (4.5%)	6 (9.1%)	18 (27.3%)	10 (15.2%)	13 (19.7%)	6 (9.1%)	5 (7.6%)
Week 38	66	4 (6.1%)	1 (1.5%)	3 (4.5%)	7 (10.6%)	17 (25.8%)	11 (16.7%)	13 (19.7%)	5 (7.6%)	5 (7.6%)
Week 40	63	3 (4.8%)	4 (6.3%)	1 (1.6%)	8 (12.7%)	14 (22.2%)	7 (11.1%)	13 (20.6%)	7 (11.1%)	6 (9.5%)
Week 42	62	2 (3.2%)	5 (8.1%)	1 (1.6%)	8 (12.9%)	13 (21.0%)	7 (11.3%)	13 (21.0%)	7 (11.3%)	6 (9.7%)
Week 44	61	5 (8.2%)	3 (4.9%)	0	11 (18.0%)	9 (14.8%)	11 (18.0%)	9 (14.8%)	6 (9.8%)	7 (11.5%)
Week 46	61	5 (8.2%)	3 (4.9%)	0	11 (18.0%)	9 (14.8%)	11 (18.0%)	9 (14.8%)	6 (9.8%)	7 (11.5%)
Week 48	61	6 (9.8%)	2 (3.3%)	0	9 (14.8%)	12 (19.7%)	11 (18.0%)	8 (13.1%)	6 (9.8%)	7 (11.5%)
Week 50	61	7 (11.5%)	2 (3.3%)	0	9 (14.8%)	12 (19.7%)	11 (18.0%)	8 (13.1%)	5 (8.2%)	7 (11.5%)

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	10	0	0	0	0	0	10 (100.0%)	0	0	0
Week 2	10	0	0	0	0	1 (10.0%)	9 (90.0%)	0	0	0
Week 4	10	0	0	0	0	2 (20.0%)	7 (70.0%)	1 (10.0%)	0	0
Week 6	10	1 (10.0%)	0	0	0	1 (10.0%)	7 (70.0%)	1 (10.0%)	0	0
Week 8	10	1 (10.0%)	0	0	1 (10.0%)	2 (20.0%)	5 (50.0%)	0	1 (10.0%)	0
Week 10	10	0	0	0	2 (20.0%)	2 (20.0%)	5 (50.0%)	0	1 (10.0%)	0
Week 12	10	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	1 (10.0%)	5 (50.0%)	0	0	1 (10.0%)
Week 14	10	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	1 (10.0%)	5 (50.0%)	0	0	1 (10.0%)
Week 16	10	1 (10.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	3 (30.0%)	1 (10.0%)	0	1 (10.0%)
Week 18	10	2 (20.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	4 (40.0%)	0	0	1 (10.0%)
Week 20	10	0	2 (20.0%)	1 (10.0%)	1 (10.0%)	2 (20.0%)	2 (20.0%)	1 (10.0%)	0	1 (10.0%)
Week 22	10	0	2 (20.0%)	1 (10.0%)	1 (10.0%)	2 (20.0%)	2 (20.0%)	1 (10.0%)	0	1 (10.0%)
Week 24	10	1 (10.0%)	1 (10.0%)	1 (10.0%)	3 (30.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 26	10	2 (20.0%)	1 (10.0%)	1 (10.0%)	2 (20.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 28	10	2 (20.0%)	1 (10.0%)	2 (20.0%)	2 (20.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 30	10	2 (20.0%)	1 (10.0%)	2 (20.0%)	2 (20.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 32	10	2 (20.0%)	2 (20.0%)	2 (20.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 33	10	2 (20.0%)	2 (20.0%)	2 (20.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 34	10	2 (20.0%)	2 (20.0%)	2 (20.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 35	10	2 (20.0%)	2 (20.0%)	2 (20.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 36	10	2 (20.0%)	3 (30.0%)	1 (10.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 38	10	2 (20.0%)	3 (30.0%)	1 (10.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 40	10	3 (30.0%)	2 (20.0%)	1 (10.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 42	10	3 (30.0%)	2 (20.0%)	1 (10.0%)	1 (10.0%)	0	1 (10.0%)	1 (10.0%)	0	1 (10.0%)
Week 44	10	3 (30.0%)	2 (20.0%)	1 (10.0%)	1 (10.0%)	0	2 (20.0%)	0	0	1 (10.0%)
Week 46	10	3 (30.0%)	2 (20.0%)	1 (10.0%)	1 (10.0%)	0	2 (20.0%)	0	0	1 (10.0%)
Week 48	10	5 (50.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	0	0	0
Week 50	10	5 (50.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	1 (10.0%)	0	0	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	9	0	0	0	0	0	9 (100.0%)	0	0	0
Week 2	9	0	0	0	0	0	9 (100.0%)	0	0	0
Week 4	9	0	0	0	0	0	7 (77.8%)	2 (22.2%)	0	0
Week 6	9	0	0	0	0	0	7 (77.8%)	2 (22.2%)	0	0
Week 8	9	0	0	0	0	2 (22.2%)	5 (55.6%)	1 (11.1%)	1 (11.1%)	0
Week 10	9	0	0	0	0	3 (33.3%)	4 (44.4%)	1 (11.1%)	1 (11.1%)	0
Week 12	9	1 (11.1%)	0	0	0	2 (22.2%)	4 (44.4%)	2 (22.2%)	0	0
Week 14	9	2 (22.2%)	0	0	0	3 (33.3%)	2 (22.2%)	2 (22.2%)	0	0
Week 16	9	3 (33.3%)	0	0	1 (11.1%)	1 (11.1%)	2 (22.2%)	0	2 (22.2%)	0
Week 18	9	1 (11.1%)	0	0	2 (22.2%)	2 (22.2%)	2 (22.2%)	0	2 (22.2%)	0
Week 20	9	1 (11.1%)	0	0	3 (33.3%)	1 (11.1%)	0	2 (22.2%)	0	2 (22.2%)
Week 22	9	0	0	0	4 (44.4%)	1 (11.1%)	0	2 (22.2%)	0	2 (22.2%)
Week 24	9	0	0	1 (11.1%)	4 (44.4%)	0	0	0	2 (22.2%)	2 (22.2%)
Week 26	9	0	0	2 (22.2%)	3 (33.3%)	0	0	0	2 (22.2%)	2 (22.2%)
Week 28	9	0	0	1 (11.1%)	3 (33.3%)	1 (11.1%)	0	0	3 (33.3%)	1 (11.1%)
Week 30	9	0	0	1 (11.1%)	3 (33.3%)	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)
Week 32	9	0	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	2 (22.2%)	1 (11.1%)	1 (11.1%)
Week 33	9	0	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	2 (22.2%)	1 (11.1%)	1 (11.1%)
Week 34	9	0	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	2 (22.2%)	1 (11.1%)	1 (11.1%)
Week 35	9	0	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	2 (22.2%)	1 (11.1%)	1 (11.1%)
Week 36	9	1 (11.1%)	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Week 38	9	0	1 (11.1%)	0	2 (22.2%)	2 (22.2%)	1 (11.1%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Week 40	9	0	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	2 (22.2%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Week 42	9	1 (11.1%)	1 (11.1%)	0	2 (22.2%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Week 44	9	1 (11.1%)	1 (11.1%)	0	2 (22.2%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Week 46	9	0	1 (11.1%)	0	3 (33.3%)	0	2 (22.2%)	1 (11.1%)	1 (11.1%)	1 (11.1%)
Week 48	9	0	1 (11.1%)	0	3 (33.3%)	0	2 (22.2%)	1 (11.1%)	2 (22.2%)	0
Week 50	9	0	1 (11.1%)	0	3 (33.3%)	0	2 (22.2%)	1 (11.1%)	2 (22.2%)	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	19	0	0	0	0	0	19 (100.0%)	0	0	0
Week 2	19	0	0	0	0	1 (5.3%)	18 (94.7%)	0	0	0
Week 4	19	0	0	0	0	2 (10.5%)	14 (73.7%)	3 (15.8%)	0	0
Week 6	19	1 (5.3%)	0	0	0	1 (5.3%)	14 (73.7%)	3 (15.8%)	0	0
Week 8	19	1 (5.3%)	0	0	1 (5.3%)	4 (21.1%)	10 (52.6%)	1 (5.3%)	2 (10.5%)	0
Week 10	19	0	0	0	2 (10.5%)	5 (26.3%)	9 (47.4%)	1 (5.3%)	2 (10.5%)	0
Week 12	19	2 (10.5%)	0	1 (5.3%)	1 (5.3%)	3 (15.8%)	9 (47.4%)	2 (10.5%)	0	1 (5.3%)
Week 14	19	3 (15.8%)	0	1 (5.3%)	1 (5.3%)	4 (21.1%)	7 (36.8%)	2 (10.5%)	0	1 (5.3%)
Week 16	19	4 (21.1%)	1 (5.3%)	1 (5.3%)	2 (10.5%)	2 (10.5%)	5 (26.3%)	1 (5.3%)	2 (10.5%)	1 (5.3%)
Week 18	19	3 (15.8%)	1 (5.3%)	0	3 (15.8%)	3 (15.8%)	6 (31.6%)	0	2 (10.5%)	1 (5.3%)
Week 20	19	1 (5.3%)	2 (10.5%)	1 (5.3%)	4 (21.1%)	3 (15.8%)	2 (10.5%)	3 (15.8%)	0	3 (15.8%)
Week 22	19	0	2 (10.5%)	1 (5.3%)	5 (26.3%)	3 (15.8%)	2 (10.5%)	3 (15.8%)	0	3 (15.8%)
Week 24	19	1 (5.3%)	1 (5.3%)	2 (10.5%)	7 (36.8%)	1 (5.3%)	1 (5.3%)	1 (5.3%)	2 (10.5%)	3 (15.8%)
Week 26	19	2 (10.5%)	1 (5.3%)	3 (15.8%)	5 (26.3%)	1 (5.3%)	1 (5.3%)	1 (5.3%)	2 (10.5%)	3 (15.8%)
Week 28	19	2 (10.5%)	1 (5.3%)	3 (15.8%)	5 (26.3%)	1 (5.3%)	1 (5.3%)	1 (5.3%)	3 (15.8%)	2 (10.5%)
Week 30	19	2 (10.5%)	1 (5.3%)	3 (15.8%)	5 (26.3%)	1 (5.3%)	1 (5.3%)	3 (15.8%)	1 (5.3%)	2 (10.5%)
Week 32	19	2 (10.5%)	3 (15.8%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)
Week 33	19	2 (10.5%)	3 (15.8%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)
Week 34	19	2 (10.5%)	3 (15.8%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)
Week 35	19	2 (10.5%)	3 (15.8%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	2 (10.5%)
Week 36	19	3 (15.8%)	4 (21.1%)	1 (5.3%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	2 (10.5%)	1 (5.3%)	2 (10.5%)
Week 38	19	2 (10.5%)	4 (21.1%)	1 (5.3%)	3 (15.8%)	2 (10.5%)	2 (10.5%)	2 (10.5%)	1 (5.3%)	2 (10.5%)
Week 40	19	3 (15.8%)	3 (15.8%)	1 (5.3%)	3 (15.8%)	1 (5.3%)	3 (15.8%)	2 (10.5%)	1 (5.3%)	2 (10.5%)
Week 42	19	4 (21.1%)	3 (15.8%)	1 (5.3%)	3 (15.8%)	0	3 (15.8%)	2 (10.5%)	1 (5.3%)	2 (10.5%)
Week 44	19	4 (21.1%)	3 (15.8%)	1 (5.3%)	3 (15.8%)	0	4 (21.1%)	1 (5.3%)	1 (5.3%)	2 (10.5%)
Week 46	19	3 (15.8%)	3 (15.8%)	1 (5.3%)	4 (21.1%)	0	4 (21.1%)	1 (5.3%)	1 (5.3%)	2 (10.5%)
Week 48	19	5 (26.3%)	2 (10.5%)	1 (5.3%)	4 (21.1%)	1 (5.3%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	0
Week 50	19	5 (26.3%)	2 (10.5%)	1 (5.3%)	4 (21.1%)	1 (5.3%)	3 (15.8%)	1 (5.3%)	2 (10.5%)	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)


Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	25	0	0	0	0	0	25 (100.0%)	0	0	0
Week 2	24	0	0	0	0	3 (12.5%)	21 (87.5%)	0	0	0
Week 4	24	3 (12.5%)	0	0	0	3 (12.5%)	14 (58.3%)	4 (16.7%)	0	0
Week 6	24	3 (12.5%)	0	0	0	3 (12.5%)	14 (58.3%)	4 (16.7%)	0	0
Week 8	22	5 (22.7%)	0	0	1 (4.5%)	2 (9.1%)	12 (54.5%)	1 (4.5%)	1 (4.5%)	0
Week 10	21	5 (23.8%)	0	0	1 (4.8%)	2 (9.5%)	12 (57.1%)	0	1 (4.8%)	0
Week 12	21	4 (19.0%)	0	0	3 (14.3%)	2 (9.5%)	10 (47.6%)	1 (4.8%)	0	1 (4.8%)
Week 14	21	4 (19.0%)	0	0	3 (14.3%)	2 (9.5%)	10 (47.6%)	1 (4.8%)	0	1 (4.8%)
Week 16	21	3 (14.3%)	0	0	5 (23.8%)	2 (9.5%)	9 (42.9%)	0	1 (4.8%)	1 (4.8%)
Week 18	21	3 (14.3%)	0	0	5 (23.8%)	2 (9.5%)	9 (42.9%)	0	1 (4.8%)	1 (4.8%)
Week 20	21	3 (14.3%)	0	0	5 (23.8%)	2 (9.5%)	7 (33.3%)	2 (9.5%)	1 (4.8%)	1 (4.8%)
Week 22	21	3 (14.3%)	0	0	5 (23.8%)	2 (9.5%)	7 (33.3%)	2 (9.5%)	1 (4.8%)	1 (4.8%)
Week 24	21	3 (14.3%)	0	1 (4.8%)	4 (19.0%)	2 (9.5%)	7 (33.3%)	0	3 (14.3%)	1 (4.8%)
Week 26	20	3 (15.0%)	0	1 (5.0%)	4 (20.0%)	2 (10.0%)	6 (30.0%)	0	3 (15.0%)	1 (5.0%)
Week 28	20	1 (5.0%)	1 (5.0%)	1 (5.0%)	5 (25.0%)	3 (15.0%)	5 (25.0%)	1 (5.0%)	2 (10.0%)	1 (5.0%)
Week 30	19	1 (5.3%)	1 (5.3%)	2 (10.5%)	4 (21.1%)	2 (10.5%)	5 (26.3%)	1 (5.3%)	2 (10.5%)	1 (5.3%)
Week 32	19	1 (5.3%)	2 (10.5%)	2 (10.5%)	3 (15.8%)	2 (10.5%)	5 (26.3%)	1 (5.3%)	2 (10.5%)	1 (5.3%)
Week 33	19	1 (5.3%)	2 (10.5%)	3 (15.8%)	2 (10.5%)	2 (10.5%)	5 (26.3%)	1 (5.3%)	2 (10.5%)	1 (5.3%)
Week 34	19	1 (5.3%)	2 (10.5%)	3 (15.8%)	2 (10.5%)	2 (10.5%)	5 (26.3%)	1 (5.3%)	2 (10.5%)	1 (5.3%)
Week 35	19	2 (10.5%)	2 (10.5%)	2 (10.5%)	2 (10.5%)	2 (10.5%)	5 (26.3%)	1 (5.3%)	2 (10.5%)	1 (5.3%)
Week 36	19	2 (10.5%)	2 (10.5%)	3 (15.8%)	0	3 (15.8%)	4 (21.1%)	2 (10.5%)	2 (10.5%)	1 (5.3%)
Week 38	19	2 (10.5%)	3 (15.8%)	2 (10.5%)	0	3 (15.8%)	4 (21.1%)	2 (10.5%)	2 (10.5%)	1 (5.3%)
Week 40	19	1 (5.3%)	3 (15.8%)	3 (15.8%)	0	2 (10.5%)	5 (26.3%)	3 (15.8%)	1 (5.3%)	1 (5.3%)
Week 42	19	1 (5.3%)	3 (15.8%)	3 (15.8%)	0	2 (10.5%)	5 (26.3%)	3 (15.8%)	1 (5.3%)	1 (5.3%)
Week 44	19	2 (10.5%)	2 (10.5%)	3 (15.8%)	0	2 (10.5%)	6 (31.6%)	3 (15.8%)	0	1 (5.3%)
Week 46	19	2 (10.5%)	2 (10.5%)	3 (15.8%)	1 (5.3%)	1 (5.3%)	6 (31.6%)	3 (15.8%)	0	1 (5.3%)
Week 48	19	2 (10.5%)	3 (15.8%)	2 (10.5%)	2 (10.5%)	1 (5.3%)	5 (26.3%)	2 (10.5%)	1 (5.3%)	1 (5.3%)
Week 50	19	2 (10.5%)	4 (21.1%)	2 (10.5%)	1 (5.3%)	1 (5.3%)	5 (26.3%)	2 (10.5%)	1 (5.3%)	1 (5.3%)

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)


Visit	n	0 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	23	0	0	0	0	23 (100.0%)	0	0	0
Week 2	23	0	0	0	0	23 (100.0%)	0	0	0
Week 4	23	0	0	0	0	11 (47.8%)	12 (52.2%)	0	0
Week 6	23	0	0	0	0	11 (47.8%)	12 (52.2%)	0	0
Week 8	21	0	0	0	1 (4.8%)	7 (33.3%)	5 (23.8%)	8 (38.1%)	0
Week 10	21	0	0	0	1 (4.8%)	7 (33.3%)	5 (23.8%)	8 (38.1%)	0
Week 12	20	1 (5.0%)	0	0	3 (15.0%)	2 (10.0%)	6 (30.0%)	2 (10.0%)	6 (30.0%)
Week 14	20	1 (5.0%)	0	0	3 (15.0%)	2 (10.0%)	6 (30.0%)	2 (10.0%)	6 (30.0%)
Week 16	20	1 (5.0%)	0	3 (15.0%)	0	3 (15.0%)	2 (10.0%)	5 (25.0%)	6 (30.0%)
Week 18	20	0	0	4 (20.0%)	0	3 (15.0%)	2 (10.0%)	5 (25.0%)	6 (30.0%)
Week 20	20	0	0	4 (20.0%)	1 (5.0%)	3 (15.0%)	1 (5.0%)	6 (30.0%)	5 (25.0%)
Week 22	19	2 (10.5%)	0	4 (21.1%)	0	3 (15.8%)	1 (5.3%)	5 (26.3%)	4 (21.1%)
Week 24	19	2 (10.5%)	0	3 (15.8%)	2 (10.5%)	2 (10.5%)	0	5 (26.3%)	5 (26.3%)
Week 26	19	1 (5.3%)	0	5 (26.3%)	1 (5.3%)	2 (10.5%)	0	5 (26.3%)	5 (26.3%)
Week 28	19	0	0	5 (26.3%)	2 (10.5%)	1 (5.3%)	3 (15.8%)	2 (10.5%)	6 (31.6%)
Week 30	19	0	0	5 (26.3%)	2 (10.5%)	1 (5.3%)	3 (15.8%)	3 (15.8%)	5 (26.3%)
Week 32	19	1 (5.3%)	0	4 (21.1%)	1 (5.3%)	4 (21.1%)	2 (10.5%)	1 (5.3%)	6 (31.6%)
Week 33	19	1 (5.3%)	0	4 (21.1%)	1 (5.3%)	4 (21.1%)	2 (10.5%)	1 (5.3%)	6 (31.6%)
Week 34	19	0	1 (5.3%)	4 (21.1%)	1 (5.3%)	4 (21.1%)	2 (10.5%)	1 (5.3%)	6 (31.6%)
Week 35	19	0	1 (5.3%)	4 (21.1%)	1 (5.3%)	4 (21.1%)	2 (10.5%)	1 (5.3%)	6 (31.6%)
Week 36	19	0	1 (5.3%)	4 (21.1%)	2 (10.5%)	3 (15.8%)	3 (15.8%)	0	6 (31.6%)
Week 38	19	0	1 (5.3%)	4 (21.1%)	2 (10.5%)	3 (15.8%)	3 (15.8%)	0	6 (31.6%)
Week 40	18	0	1 (5.6%)	4 (22.2%)	2 (11.1%)	3 (16.7%)	3 (16.7%)	0	5 (27.8%)
Week 42	18	1 (5.6%)	1 (5.6%)	4 (22.2%)	2 (11.1%)	2 (11.1%)	3 (16.7%)	0	5 (27.8%)
Week 44	17	1 (5.9%)	1 (5.9%)	4 (23.5%)	2 (11.8%)	2 (11.8%)	1 (5.9%)	2 (11.8%)	4 (23.5%)
Week 46	17	1 (5.9%)	1 (5.9%)	4 (23.5%)	2 (11.8%)	2 (11.8%)	1 (5.9%)	2 (11.8%)	4 (23.5%)
Week 48	16	0	1 (6.3%)	3 (18.8%)	5 (31.3%)	1 (6.3%)	1 (6.3%)	1 (6.3%)	4 (25.0%)
Week 50	16	0	1 (6.3%)	3 (18.8%)	5 (31.3%)	1 (6.3%)	1 (6.3%)	1 (6.3%)	4 (25.0%)

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	48	0	0	0	0	0	48 (100.0%)	0	0	0
Week 2	47	0	0	0	0	3 (6.4%)	44 (93.6%)	0	0	0
Week 4	47	3 (6.4%)	0	0	0	3 (6.4%)	25 (53.2%)	16 (34.0%)	0	0
Week 6	47	3 (6.4%)	0	0	0	3 (6.4%)	25 (53.2%)	16 (34.0%)	0	0
Week 8	43	5 (11.6%)	0	0	1 (2.3%)	3 (7.0%)	19 (44.2%)	6 (14.0%)	9 (20.9%)	0
Week 10	42	5 (11.9%)	0	0	1 (2.4%)	3 (7.1%)	19 (45.2%)	5 (11.9%)	9 (21.4%)	0
Week 12	41	5 (12.2%)	0	0	3 (7.3%)	5 (12.2%)	12 (29.3%)	7 (17.1%)	2 (4.9%)	7 (17.1%)
Week 14	41	5 (12.2%)	0	0	3 (7.3%)	5 (12.2%)	12 (29.3%)	7 (17.1%)	2 (4.9%)	7 (17.1%)
Week 16	41	4 (9.8%)	0	0	8 (19.5%)	2 (4.9%)	12 (29.3%)	2 (4.9%)	6 (14.6%)	7 (17.1%)
Week 18	41	3 (7.3%)	0	0	9 (22.0%)	2 (4.9%)	12 (29.3%)	2 (4.9%)	6 (14.6%)	7 (17.1%)
Week 20	41	3 (7.3%)	0	0	9 (22.0%)	3 (7.3%)	10 (24.4%)	3 (7.3%)	7 (17.1%)	6 (14.6%)
Week 22	40	5 (12.5%)	0	0	9 (22.5%)	2 (5.0%)	10 (25.0%)	3 (7.5%)	6 (15.0%)	5 (12.5%)
Week 24	40	5 (12.5%)	0	1 (2.5%)	7 (17.5%)	4 (10.0%)	9 (22.5%)	0	8 (20.0%)	6 (15.0%)
Week 26	39	4 (10.3%)	0	1 (2.6%)	9 (23.1%)	3 (7.7%)	8 (20.5%)	0	8 (20.5%)	6 (15.4%)
Week 28	39	1 (2.6%)	1 (2.6%)	1 (2.6%)	10 (25.6%)	5 (12.8%)	6 (15.4%)	4 (10.3%)	4 (10.3%)	7 (17.9%)
Week 30	38	1 (2.6%)	1 (2.6%)	2 (5.3%)	9 (23.7%)	4 (10.5%)	6 (15.8%)	4 (10.5%)	5 (13.2%)	6 (15.8%)
Week 32	38	2 (5.3%)	2 (5.3%)	2 (5.3%)	7 (18.4%)	3 (7.9%)	9 (23.7%)	3 (7.9%)	3 (7.9%)	7 (18.4%)
Week 33	38	2 (5.3%)	2 (5.3%)	3 (7.9%)	6 (15.8%)	3 (7.9%)	9 (23.7%)	3 (7.9%)	3 (7.9%)	7 (18.4%)
Week 34	38	1 (2.6%)	2 (5.3%)	4 (10.5%)	6 (15.8%)	3 (7.9%)	9 (23.7%)	3 (7.9%)	3 (7.9%)	7 (18.4%)
Week 35	38	2 (5.3%)	2 (5.3%)	3 (7.9%)	6 (15.8%)	3 (7.9%)	9 (23.7%)	3 (7.9%)	3 (7.9%)	7 (18.4%)
Week 36	38	2 (5.3%)	2 (5.3%)	4 (10.5%)	4 (10.5%)	5 (13.2%)	7 (18.4%)	5 (13.2%)	2 (5.3%)	7 (18.4%)
Week 38	38	2 (5.3%)	3 (7.9%)	3 (7.9%)	4 (10.5%)	5 (13.2%)	7 (18.4%)	5 (13.2%)	2 (5.3%)	7 (18.4%)
Week 40	37	1 (2.7%)	3 (8.1%)	4 (10.8%)	4 (10.8%)	4 (10.8%)	8 (21.6%)	6 (16.2%)	1 (2.7%)	6 (16.2%)
Week 42	37	2 (5.4%)	3 (8.1%)	4 (10.8%)	4 (10.8%)	4 (10.8%)	7 (18.9%)	6 (16.2%)	1 (2.7%)	6 (16.2%)
Week 44	36	3 (8.3%)	2 (5.6%)	4 (11.1%)	4 (11.1%)	4 (11.1%)	8 (22.2%)	4 (11.1%)	2 (5.6%)	5 (13.9%)
Week 46	36	3 (8.3%)	2 (5.6%)	4 (11.1%)	5 (13.9%)	3 (8.3%)	8 (22.2%)	4 (11.1%)	2 (5.6%)	5 (13.9%)
Week 48	35	2 (5.7%)	3 (8.6%)	3 (8.6%)	5 (14.3%)	6 (17.1%)	6 (17.1%)	3 (8.6%)	2 (5.7%)	5 (14.3%)
Week 50	35	2 (5.7%)	4 (11.4%)	3 (8.6%)	4 (11.4%)	6 (17.1%)	6 (17.1%)	3 (8.6%)	2 (5.7%)	5 (14.3%)



The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0



The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0

図 2.7.3.6-40　前治療として使用した ESA の種類別（DA 又は PEGOL）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19353、FAS）

表 2.7.3.6-81 前治療として使用した ESA の種類別（DA 又は PEGOL）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19353、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total


		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=22)	Screening -2	22	11.19	0.92	10.0	11.10	12.8						
	Screening -1	22	11.18	0.83	9.9	11.05	12.7						
	Week 0	22	10.95	0.87	9.8	10.90	12.6						
	Baseline	22	11.11	0.80	10.0	10.97	12.5						
	Week 2	22	10.66	1.06	8.6	10.65	12.6	22	-0.45	0.68	-1.8	-0.47	0.7
	Week 4	22	10.72	1.35	8.5	10.45	13.4	22	-0.38	1.00	-1.9	-0.50	1.3
	Week 6	22	10.64	1.51	7.9	10.65	12.9	22	-0.47	1.17	-2.4	-0.48	1.3
	Week 8	20	11.19	1.51	8.5	11.40	13.7	20	0.02	1.27	-2.2	-0.02	2.3
	Week 12	20	11.30	1.14	9.4	11.40	13.6	20	0.13	1.12	-1.6	0.38	1.6
	Week 16	20	11.80	1.08	9.6	12.10	13.5	20	0.64	1.37	-2.1	0.65	2.6
	Week 20	20	11.96	1.15	9.5	11.95	13.8	20	0.79	1.49	-2.1	1.03	3.8
	Week 24	20	11.76	1.11	9.7	11.55	13.9	20	0.60	1.66	-2.8	0.55	3.8
	Week 28	19	11.91	1.08	9.3	11.80	14.2	19	0.75	1.48	-3.2	1.07	3.4
	Week 30	19	11.82	1.00	9.9	11.90	13.5	19	0.65	1.44	-2.6	0.93	2.8
	Week 32	19	11.82	0.98	9.8	11.80	13.3	19	0.65	1.44	-2.7	0.73	3.3
	Week 34	19	11.52	0.86	9.9	11.40	13.0	19	0.36	1.32	-1.7	0.53	3.0
	Week 36	19	11.67	0.85	10.1	11.50	13.1	19	0.50	1.27	-1.5	0.43	2.6
	Evaluation period	22	11.48	1.03	8.3	11.51	13.0	22	0.38	1.31	-2.2	0.45	2.8
	End of Follow-Up	22	10.60	1.29	7.6	10.60	13.4	22	-0.51	1.30	-2.9	-0.83	2.4

The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period


Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=27)	Screening -2	27	11.32	1.05	9.8	11.30	13.1						
	Screening -1	27	11.40	0.92	9.7	11.40	13.1						
	Week 0	27	11.17	0.90	9.3	11.20	12.4						
	Baseline	27	11.30	0.86	9.8	11.43	12.7						
	Week 2	27	10.70	0.94	8.5	11.00	12.4	27	-0.59	0.67	-1.7	-0.83	1.0
	Week 4	27	10.48	1.01	8.8	10.50	12.1	27	-0.82	0.93	-2.3	-1.03	1.3
	Week 6	26	10.25	0.98	7.9	10.45	11.7	26	-1.01	0.94	-2.9	-1.18	0.4
	Week 8	25	10.30	1.26	7.3	10.30	12.8	25	-0.99	1.25	-3.5	-0.97	1.4
	Week 12	22	11.00	1.49	8.6	11.25	15.0	22	-0.36	1.57	-2.9	-0.65	3.6
	Week 16	21	11.43	1.51	8.2	11.40	13.7	21	0.11	1.49	-3.3	0.37	2.4
	Week 20	18	11.66	1.28	8.3	11.70	13.5	18	0.34	1.08	-3.2	0.48	1.4
	Week 24	18	11.54	1.40	8.2	11.70	14.1	18	0.23	1.76	-3.3	-0.10	3.2
	Week 28	16	10.98	1.01	8.6	11.00	12.7	16	-0.37	1.38	-3.0	0.05	1.1
	Week 30	16	11.18	1.05	8.3	11.45	12.5	16	-0.16	1.50	-3.2	0.20	2.6
	Week 32	16	11.14	1.03	8.6	11.15	12.6	16	-0.20	1.38	-2.9	0.35	1.9
	Week 34	16	11.29	1.26	8.0	11.55	12.6	16	-0.06	1.45	-3.5	-0.03	2.1
	Week 36	15	12.31	1.29	9.8	12.10	14.7	15	0.98	1.48	-1.2	0.47	3.8
	Evaluation period	27	10.92	1.42	7.3	11.15	13.0	27	-0.38	1.55	-3.5	-0.41	2.6
	End of Follow-Up	26	10.52	1.30	8.6	10.50	13.9	26	-0.77	1.32	-3.5	-0.95	3.6

The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period



The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0



The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0

図 2.7.3.6-41　前治療として使用した DA の投与量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19353、FAS）

表 2.7.3.6-82 前治療として使用した DA の投与量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19353、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 30.000 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=17)	Screening -2	17	11.27	0.85	10.1	11.20	12.8						
	Screening -1	17	11.22	0.77	9.9	11.00	12.7						
	Week 0	17	10.99	0.81	9.8	10.90	12.3						
	Baseline	17	11.16	0.73	10.0	10.97	12.5						
	Week 2	17	10.83	0.94	8.6	10.70	12.6	17	-0.33	0.71	-1.8	-0.13	0.7
	Week 4	17	10.92	1.27	8.5	10.70	13.4	17	-0.25	1.03	-1.9	-0.43	1.3
	Week 6	17	10.95	1.36	8.2	11.20	12.9	17	-0.22	1.15	-2.4	0.07	1.3
	Week 8	16	11.43	1.54	8.5	11.60	13.7	16	0.23	1.33	-2.2	0.48	2.3
	Week 12	16	11.33	1.25	9.4	11.40	13.6	16	0.13	1.14	-1.6	0.38	1.6
	Week 16	16	11.96	1.06	9.8	12.20	13.5	16	0.76	1.23	-1.3	0.65	2.6
	Week 20	16	12.02	1.08	9.5	12.05	13.6	16	0.82	1.17	-1.6	1.03	2.6
	Week 24	16	11.69	1.12	9.7	11.45	13.9	16	0.49	1.58	-2.8	0.55	2.9
	Week 28	15	11.80	1.09	9.3	11.70	14.2	15	0.60	1.43	-3.2	1.07	2.4
	Week 30	15	11.67	0.96	9.9	11.80	13.5	15	0.46	1.37	-2.6	0.93	2.2
	Week 32	15	11.59	0.87	9.8	11.70	13.1	15	0.38	1.25	-2.7	0.73	2.1
	Week 34	15	11.43	0.80	9.9	11.40	13.0	15	0.23	1.02	-1.7	0.53	1.8
	Week 36	15	11.68	0.90	10.1	11.50	13.1	15	0.48	1.16	-1.5	0.43	2.6
	Evaluation period	17	11.52	0.72	10.2	11.40	13.0	17	0.35	1.03	-2.0	0.57	1.7
	End of Follow-Up	17	10.89	1.16	8.7	10.70	13.4	17	-0.27	1.26	-2.4	-0.37	2.4

The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 30.000 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=5)	Screening -2	5	10.90	1.20	10.0	10.10	12.4						
	Screening -1	5	11.02	1.12	9.9	11.10	12.7						
	Week 0	5	10.82	1.14	9.9	10.30	12.6						
	Baseline	5	10.91	1.09	10.0	10.47	12.4						
	Week 2	5	10.08	1.36	9.1	9.30	12.2	5	-0.83	0.41	-1.4	-0.90	-0.2
	Week 4	5	10.06	1.54	8.6	10.00	12.5	5	-0.85	0.86	-1.9	-1.10	0.1
	Week 6	5	9.60	1.66	7.9	9.60	12.1	5	-1.31	0.90	-2.2	-1.57	-0.3
	Week 8	4	10.23	1.07	9.2	10.00	11.7	4	-0.80	0.52	-1.5	-0.77	-0.2
	Week 12	4	11.18	0.57	10.6	11.15	11.8	4	0.15	1.20	-1.1	0.08	1.5
	Week 16	4	11.18	1.07	9.6	11.55	12.0	4	0.15	1.97	-2.1	0.33	2.0
	Week 20	4	11.70	1.55	10.3	11.35	13.8	4	0.68	2.68	-2.1	0.52	3.8
	Week 24	4	12.05	1.18	11.2	11.60	13.8	4	1.03	2.19	-1.2	0.77	3.8
	Week 28	4	12.33	1.09	11.0	12.45	13.4	4	1.30	1.75	-0.7	1.23	3.4
	Week 30	4	12.38	1.09	10.8	12.70	13.3	4	1.35	1.71	-0.9	1.73	2.8
	Week 32	4	12.68	0.99	11.2	13.10	13.3	4	1.65	1.85	-0.5	1.88	3.3
	Week 34	4	11.85	1.14	10.6	11.90	13.0	4	0.83	2.29	-1.2	0.77	3.0
	Week 36	4	11.63	0.73	10.7	11.75	12.3	4	0.60	1.85	-1.0	0.57	2.3
	Evaluation period	5	11.37	1.88	8.3	12.25	12.8	5	0.45	2.19	-2.2	-0.18	2.8
	End of Follow-Up	5	9.60	1.33	7.6	10.20	10.8	5	-1.31	1.21	-2.9	-1.47	0.5

The baseline Hb level is defined as the mean of the last two Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period